Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

AIDS

Volumn 25, Issue 3, 2011, Pages 367-377

  Soliman, Elsayed Z ^a   Lundgren, Jens D ^b   Roediger, Mollie P ^c   Duprez, Daniel A ^d   Temesgen, Zelalem ^e   Bickel, Markus ^f   Shlay, Judith C ^g   Somboonwit, Charurut ^h   Reiss, Peter ⁱ   Stein, James H ^j   Neaton, James D ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c California State College   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e MAYO CLINIC   (United States)

^f GOETHE UNIVERSITY   (Germany)

^g Denver Community Programs for Clinical Research on AIDS   (United States)

^h UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁱ AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^j UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

more..

Author keywords

electrocardiogram; HIV AIDS; PR; protease inhibitors; QTc

Indexed keywords

ATAZANAVIR; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERMITTENT THERAPY; ELECTROCARDIOGRAPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADULT; ANTI-RETROVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HIV-1; HUMANS; LONG QT SYNDROME; MALE; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79551597268     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328341dcc0     Document Type: Article

References (29)

1. Singh M, Arora R, Jawad E. HIV protease inhibitors induced prolongation of the QT interval: electrophysiology and clinical implications. Am J Ther 2009 [Epub ahead of print].
2. Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682-686.
3. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007; 44:e67-e68.
4. Chinello P, Lisena FP, Angeletti C, Boumis E, Papetti F, Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect 2007; 54:597-602.
5. Rathbun CR, Liedtke MD, Blevins SM, Harrison D, Lockhart SM, et al. Electrocardiogram abnormalities with atazanavir andLPV/ronavir. HIV Clin Trials 2009; 10:328-336.
6. Charbit B, Rosier A, Bollens D, Boccara F, Boelle PY, Koubaa A, et al. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br J Clin Pharmacol 2009; 67:76-82.
7. Busti AJ, Tsikouris JP, Peeters MJ, Das SR, Canham RM, Abdullah SM, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIVpositive patients. HIV Med 2006; 7:317-322.
8. U.S. Food and Drug Administration. Labeling changes for Kaletra reflecting new QT/QTC interval and PR interval prolongation information. April 2009. http://www.fda.gov/forcon sumers/byaudience/forpatientadvocates/ hivandaidsactivities/ucm155697.htm. [Accessed 23 April 2010]
9. U.S. Food and Drug Administration. Invirase (saquinavir): ongoing safety review of clinical trial data. February 2010. http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm201563.htm. [Accessed 23 April 2010].
10. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53:4-9.
11. The SMART Study Group. CD4R count-guided interruption of antiretroviral therapy. N Engl J Med 2006; 355:2283-2296.
12. SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving ePIodic therapy, a randomized trial. Ann Int Med 2008; 149:289-299.
13. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 2009. http://aidsinfo. nih.gov/contentfiles/AdultandAdolescentGL.pdf. [Accessed 2 February 2010].
14. Bazett HC. An analysis of the time-relations of electrocardiogram. Heart 1920; 7:353-370.
15. Fridericia S. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand 1920; 53:469-486.
16. Carruthers SG, McCall B, Cordell BA, Wu R. Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br J Clin Pharmacol 1987; 23: 259-265.
17. U.S. Food and Drug Administration. Guidance for industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/UCM129357.pdf. [Accessed 23 April 2010].
18. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3:1003-1007.
19. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004; 37:81-90.
20. Rautaharju PM, Warren JW, Calhoun HP. Estimation of QT prolongation. A persistent, avoidable error in computer electrocardiography. J Electrocardiol 1990; 23:111-117.
21. Rautaharju PM, Rautaharju F. QT prolongation and QT dispersion: a critical evaluation. Investigative Electrocardiography in Epidemiological Studies and Clinical Trials. Berlin: Springer, 2007.
22. Grandinetti A, Seifried S, Mor J, Chang HK, Theriault AG. Prevalence and risk factors for prolonged QTc in a multiethnic cohort in rural Hawaii. Clin Biochem 2005; 38:116-122.
23. Rautaharju PM, Prineas RJ, Kadish A, Larson JC, Hsia J, Lund B. Normal standards for QT and QT subintervals derived from a large ethnically diverse population of women aged 50 to 79 years (the Women's Health Initiative [WHI]). Am J Cardiol 2006; 97:730-737.
24. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109:30-35.
25. Itoh H, Horie M, Ito M, Imoto K. Arrhythmogenesis in the short-QT syndrome associated with combined HERG channel gating defects: a simulation study. Circ J 2006; 70:502-508.
26. Chou T, Knilans TK. Electrocardiography in clinical practice. 4th ed. Philadelphia, PA: W.B. Saunders; 1996.
27. Soliman EZ, Prineas RJ, Case D, Zhang ZM, Goff DC Jr. Ethnic distribution of electrocardiographic predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities Study (ARIC). Stroke 2009; 40:1204-1211.
28. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community- based cohort study. Lancet 2009; 373:739-745.
29. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009; 301:2571-2577.